About Casein kinase II subunit alpha 3
Casein kinase II subunit alpha 3 (CSNK2A3) is a protein
from Homo sapiens identified by UniProt accession
Q8NEV1, 391 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Casein kinase II subunit alpha 3 |
| UniProt accession | Q8NEV1 |
| Gene | CSNK2A3 |
| Organism | Homo sapiens |
| Length | 391 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- Okur-Chung neurodevelopmental syndrome · score 0.27
- skin pigmentation measurement · score 0.18
- urate measurement · score 0.16
- bone density · score 0.16
- alcohol drinking · score 0.15
- systolic blood pressure · score 0.15
- cerebrospinal fluid biomarker measurement · score 0.14
- dimethylamine measurement · score 0.13
- diastolic blood pressure · score 0.12
- blood phosphate measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NEV1-F1 | alphafold | PREDICTED | 88.90 | — |
Amino-acid sequence (391 residues)
MSGPVPSRAR VYTDVNTHRP REYWDYESHV VEWGNQDDYQ LVRKLGRGKY SEVFEAINIT NNEKVVVKIL KPVKKKKIKR EIKILENLRG GPNIITLADI VKDPVSRTPA LVFEHVNNTD FKQLYQTLTD YDIRFYMYEI LKALDYCHSM GIMHRDVKPH NVMIDHEHRK LRLIDWGLAE FYHPGQEYNV RVASRYFKGP ELLVDYQMYD YSLDMWRLGC MLASMIFRKE PFFHGRDNYD QLVRIAKFLG TEDLYGYIDK YNIELDPRFN DILGRHSRKR WERFVHSENQ HLVSPEALDF LDKLLRYDHQ SRLTAREAME HPYFYTVVKD QARMGSSSMP GGSTPVSSAN VMSGISSVPT PSPLGPLAGS PVIAAANPLG MPVPAATGAQ Q
Explore Casein kinase II subunit alpha 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets